This article examines the degree to which effective supply chains will be a critical success factor for anti-Covid-19 vaccines. While some believe that the potential lack of ampoules, needles or raw materials will endanger mass availability of vaccines, the real challenge will be a different one: Supply chains need to be set up and production facilities need to be built for the manufacturing of vaccines at a higher scale. The author argues that many years of experience with cross-border agreements as well as innovative technologies will be the critical factors in helping to establish these required structures.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
